Who are Levofloxacin Ophthalmic's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Zymar, Avelox, Cipro, Cipro, Peflacine, ENOXA®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/levofloxacin-ophthalmic.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Levofloxacin Ophthalmic — Competitive Intelligence Brief

Levofloxacin Ophthalmic (Levofloxacin Ophthalmic) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Fluoroquinolone. Area: Infectious Disease.

marketed Fluoroquinolone DNA gyrase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Levofloxacin Ophthalmic (Levofloxacin Ophthalmic) — National University of Malaysia. Levofloxacin ophthalmic is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase, leading to bacterial cell death.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Levofloxacin Ophthalmic TARGET	Levofloxacin Ophthalmic	National University of Malaysia	marketed	Fluoroquinolone	DNA gyrase
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Avelox	moxifloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic (fourth-generation)	DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A	1999-12-10
Cipro	ciprofloxacin	Bayer AG	marketed	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Cipro	Ciprofloxacin	Alk Abello	marketed	Fluoroquinolone	DNA gyrase	1987-01-01
Peflacine	PEFLOXACIN		marketed	pefloxacin	Cytochrome P450 1A2, DNA gyrase subunit A, DNA gyrase subunit B
ENOXA®	ENOXA®	Les Laboratoires des Médicaments Stériles	marketed		RISC-loading complex subunit TARBP2, V-type proton ATPase subunit B, brain isoform, DNA gyrase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2029-04-21 — Cipro · 11369566 · Formulation · US
2029-04-21 — Cipro · 9603796 · Compound · US
2029-04-21 — Cipro · 9205048 · Method of Use · US
2029-12-11 — Cipro · 9233068 · Formulation · US
2030-04-27 — Cipro · 8318817 · Method of Use · US
2035-07-01 — Cipro · 9220796 · Formulation · US
2037-11-12 — Cipro · 11040004 · Method of Use · US
2038-11-27 — Cipro · 11246863 · Formulation · US

Sponsor landscape (Fluoroquinolone class)

Alk Abello · 1 drug in this class
Innovative Medical · 1 drug in this class
International Association Psychosomatics And Health Therapy · 1 drug in this class
National University of Malaysia · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Levofloxacin Ophthalmic — Competitive Intelligence Brief. https://druglandscape.com/ci/levofloxacin-ophthalmic. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab